Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy.

ABSTRACT:

Background

The clinical benefit of immune checkpoint blockade (ICB) therapy is often limited by the lack of pre-existing CD8⁺ T cells infiltrating the tumor. In principle, CD8⁺ T-cell infiltration could be promoted by therapeutic vaccination. However, this remains challenging given the paucity of vaccine platforms able to induce the strong cytotoxic CD8⁺ T-cell response required to reject tumors. A therapeutic cancer vaccine that induces a robust cytotoxic CD8⁺ T-cell response against shared tumor antigens and can be combined with ICB could improve the outcome of cancer immunotherapy.

Methods

Here, we developed a heterologous prime-boost vaccine based on a chimpanzee adenovirus (ChAdOx1) and a modified vaccinia Ankara (MVA) encodin

SUBMITTER: McAuliffe J 

PROVIDER: S-EPMC8420668 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature